Different B1 kinin receptor expression and pharmacology in endothelial cells of different origins and species.
In bovine aortic endothelial cells (BAECs), we previously demonstrated B1 and B2 kinin receptor-mediated increases in intracellular guanosine-3',5'-cyclic monophosphate (cGMP). In this study, the B2 kinin receptor agonist bradykinin increased cGMP in rat microvascular coronary endothelial cells (RMCECs) and human umbilical vein endothelial cells (HUVECs), which could be prevented with the specific B2 kinin receptor antagonist icatibant but not with the B1 kinin receptor antagonist des-Arg9-[Leu8]bradykinin or with the nonpeptide kinin receptor antagonist WIN 64338. B2 kinin receptor mRNA could be detected in all three cell types using reverse transcription-polymerase chain reaction and subsequent Southern blotting. The B1 kinin receptor agonist des-Arg9-bradykinin increased cGMP in RMCECs but not in HUVECs. The response in RMCECs could be prevented by des-Arg9-[Leu8]bradykinin as well as by WIN 64338 but not by icatibant. In BAECs, the B1 kinin receptor-mediated cGMP synthesis could be prevented by icatibant and desensitized by preincubation with des-Arg9-bradykinin as well as bradykinin. We detected B1 kinin receptor mRNA in RMCECs and HUVECs but not in BAECs. In HUVECs, the detection of B1 kinin receptor mRNA is in contradiction to the cGMP measurements. In BAECs, the atypical B1 kinin receptor pharmacology, the heterologous desensitization of the receptor and the failure to detect B1 kinin receptor mRNA cannot be explained by a typical B1 kinin receptor subtype. Thus, B2 kinin receptors with similar pharmacology are constitutively expressed in each of the three endothelial cell types. However, the endothelial cell types are heterogeneous in the expression of typical B1 kinin receptors and the pharmacology of the B1 kinin receptor-mediated responses.
Wohlfart
P
P
Hoechst-Marion-Roussel, Disease Group Cardiovascular, Frankfurt, Germany.
Dedio
J
J
Wirth
K
K
Schölkens
B A
BA
Wiemer
G
G
D000818:Animals; D001011:Aorta; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D065168:Bradykinin Receptor Antagonists; D002417:Cattle; D002478:Cells, Cultured; D003331:Coronary Vessels; D006152:Cyclic GMP / Q000378:metabolism*; D017931:DNA Primers; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008833:Microcirculation; D009281:Naphthalenes / Q000378:metabolism / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000378:metabolism / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D051381:Rats; D043783:Receptor, Bradykinin B1; D018002:Receptors, Bradykinin / Q000096:biosynthesis / Q000502:physiology*; D013045:Species Specificity; D014158:Transcription, Genetic / Q000187:drug effects*; D014471:Umbilical Veins
D065168:Bradykinin Receptor Antagonists; D017931:DNA Primers; D009281:Naphthalenes; D009943:Organophosphorus Compounds; D043783:Receptor, Bradykinin B1; D018002:Receptors, Bradykinin; C087374:WIN 64338; C051090:bradykinin, Leu(8)-des-Arg(9)-; C065679:icatibant; D006152:Cyclic GMP; D001920:Bradykinin